These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10807499)

  • 1. JTE-522 selectively inhibits cyclooxygenase-2-derived prostaglandin production in inflammatory tissues.
    Wakitani K; Tazaki H; Matsushita M; Iwamura H
    Inflamm Res; 2000 Mar; 49(3):117-22. PubMed ID: 10807499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats.
    Matsushita M; Masaki M; Yagi Y; Tanaka T; Wakitani K
    Inflamm Res; 1997 Nov; 46(11):461-6. PubMed ID: 9427067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of JTE-522, a specific inhibitor of cyclooxygenase-2, on the recurrence of allergic inflammation in rats.
    Niki H; Yamada M; Yamaki K; Mue S; Ohuchi K
    Eur J Pharmacol; 1998 Mar; 344(2-3):261-7. PubMed ID: 9600662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor.
    Li Z; Shimada Y; Kawabe A; Sato F; Maeda M; Komoto I; Hong T; Ding Y; Kaganoi J; Imamura M
    Carcinogenesis; 2001 Apr; 22(4):547-51. PubMed ID: 11285187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profile of JTE-522 as a human cyclooxygenase-2 inhibitor.
    Wakitani K; Nanayama T; Masaki M; Matsushita M
    Jpn J Pharmacol; 1998 Nov; 78(3):365-71. PubMed ID: 9869271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordant induction of prostaglandin E2 synthase with cyclooxygenase-2 leads to preferred production of prostaglandin E2 over thromboxane and prostaglandin D2 in lipopolysaccharide-stimulated rat peritoneal macrophages.
    Matsumoto H; Naraba H; Murakami M; Kudo I; Yamaki K; Ueno A; Oh-ishi S
    Biochem Biophys Res Commun; 1997 Jan; 230(1):110-4. PubMed ID: 9020023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological analysis of cyclooxygenase-1 in inflammation.
    Smith CJ; Zhang Y; Koboldt CM; Muhammad J; Zweifel BS; Shaffer A; Talley JJ; Masferrer JL; Seibert K; Isakson PC
    Proc Natl Acad Sci U S A; 1998 Oct; 95(22):13313-8. PubMed ID: 9789085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostacyclin synthase gene transfer modulates cyclooxygenase-2-derived prostanoid synthesis and inhibits neointimal formation in rat balloon-injured arteries.
    Yamada M; Numaguchi Y; Okumura K; Harada M; Naruse K; Matsui H; Ito T; Hayakawa T
    Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):256-62. PubMed ID: 11834525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines.
    Uefuji K; Ichikura T; Shinomiya N; Mochizuki H
    Anticancer Res; 2000; 20(6B):4279-84. PubMed ID: 11205258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
    Yamauchi T; Watanabe M; Hasegawa H; Nishibori H; Ishii Y; Tatematsu H; Yamamoto K; Kubota T; Kitajima M
    Anticancer Res; 2003; 23(1A):245-9. PubMed ID: 12680220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
    Song Y; Connor DT; Doubleday R; Sorenson RJ; Sercel AD; Unangst PC; Roth BD; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
    J Med Chem; 1999 Apr; 42(7):1151-60. PubMed ID: 10197959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of cyclooxygenase-2 on formation and healing of acetic acid-induced gastric ulcer in rats].
    Shen X
    Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1380-3. PubMed ID: 11930633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
    Song Y; Connor DT; Sercel AD; Sorenson RJ; Doubleday R; Unangst PC; Roth BD; Beylin VG; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
    J Med Chem; 1999 Apr; 42(7):1161-9. PubMed ID: 10197960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer.
    Mizutani Y; Kamoi K; Ukimura O; Kawauchi A; Miki T
    J Urol; 2002 Dec; 168(6):2650-4. PubMed ID: 12442003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory effect of two isoforms of COX in H. pylori-induced gastritis in mice: possible involvement of PGE2.
    Tanigawa T; Watanabe T; Hamaguchi M; Sasaki E; Tominaga K; Fujiwara Y; Oshitani N; Matsumoto T; Higuchi K; Arakawa T
    Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G148-56. PubMed ID: 12958020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
    Riendeau D; Percival MD; Brideau C; Charleson S; Dubé D; Ethier D; Falgueyret JP; Friesen RW; Gordon R; Greig G; Guay J; Mancini J; Ouellet M; Wong E; Xu L; Boyce S; Visco D; Girard Y; Prasit P; Zamboni R; Rodger IW; Gresser M; Ford-Hutchinson AW; Young RN; Chan CC
    J Pharmacol Exp Ther; 2001 Feb; 296(2):558-66. PubMed ID: 11160644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of a selective cyclooxygenase-2 inhibitor, HN-56249: a novel compound exhibiting a marked preference for the human enzyme in intact cells.
    Berg J; Fellier H; Christoph T; Kremminger P; Hartmann M; Blaschke H; Rovensky F; Towart R; Stimmeder D
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Apr; 361(4):363-72. PubMed ID: 10763850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach.
    Takeeda M; Hayashi Y; Yamato M; Murakami M; Takeuchi K
    J Physiol Pharmacol; 2004 Mar; 55(1 Pt 2):193-205. PubMed ID: 15082878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.